Voted Massachusetts Ten Leading Litigators
—The National Law Journal
Current Role:
Recent Success:
Experience:
Practice areas
Mr. Sobol's practice focuses on pharmaceutical and medical device litigation for consumer classes, large and small health plans and individuals.
Languages spoken
English
State | Status | Acquired | Updated |
---|---|---|---|
RI | Not Authorized to Practice - Removed from the Master Roll | 1993 | 07/08/2022 |
MA | Active | 1983 | 05/30/2022 |
PA | Retired | 1983 | 07/01/2022 |
Legal answers | 0 |
Legal guides | 0 |
Award name | Grantor | Date Granted |
---|---|---|
Super Lawyer | Thomson Reuters | 2015 |
Super Lawyer | Thomson Reuters | 2014 |
Super Lawyer | Thomson Reuters | 2013 |
Super Lawyer | Thomson Reuters | 2012 |
Super Lawyer | Thomson Reuters | 2011 |
Super Lawyer | Thomson Reuters | 2010 |
Super Lawyer | Thomson Reuters | 2009 |
Super Lawyer | Thomson Reuters | 2008 |
Massachusetts Ten Leading Litigators | The National Law Journal | 2000 |
Title | Company name | Duration |
---|---|---|
Partner | Hagens Berman Sobol Shapiro, LLP | 2002 - Present |
School name | Degree | Graduated |
---|---|---|
Boston University School of Law | JD - Juris Doctor | 1983 |
Clark University | 1980 |
Case name | Outcome |
---|---|
Neurontin | $142 Million Jury Verdict |
Tricor | $65.7 Million Recovery |
Zyprexa | $25 Million for the State of Connecticut |
The Major First Databank Price Rollback | |
Lupron | $150 Million Settlement |
Endorsements from fellow lawyers are an important consideration for many when selecting the right attorney. Be the first to endorse your colleague!